235 related articles for article (PubMed ID: 10560945)
1. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
2. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
3. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
5. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
6. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
8. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
Richardson DR; Mouralian C; Ponka P; Becker E
Biochim Biophys Acta; 2001 May; 1536(2-3):133-40. PubMed ID: 11406348
[TBL] [Abstract][Full Text] [Related]
9. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
10. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
11. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
12. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Wong CS; Kwok JC; Richardson DR
Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
14. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
15. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
Buss JL; Arduini E; Shephard KC; Ponka P
Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
17. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.
Lovejoy DB; Richardson DR
Blood; 2002 Jul; 100(2):666-76. PubMed ID: 12091363
[TBL] [Abstract][Full Text] [Related]
18. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
Bernhardt PV; Chin P; Sharpe PC; Wang JY; Richardson DR
J Biol Inorg Chem; 2005 Nov; 10(7):761-77. PubMed ID: 16193304
[TBL] [Abstract][Full Text] [Related]
19. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]